Evidence map›Paper›PMID 26367131›Full record

ArticlePLoS pathogens2015

The NLRP3 Inflammasome and IL-1β Accelerate Immunologically Mediated Pathology in Experimental Viral Fulminant Hepatitis.

Sheng Guo, Chengying Yang, Bo Diao, Xiaoyong Huang, Meihua Jin, Lili Chen, Weiming Yan, Qin Ning, Lixin Zheng, Yuzhang Wu and 1 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. NLRP3 inflammasome inhibition decreasesInfection and immunity · 2024
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. The NLRP3 inflammasome in viral infection (Review).Molecular medicine reports · 2023
    Review
  10. Involvement of the SIRT1-NLRP3 pathway in the inflammatory response.Cell communication and signaling : CCS · 2023
    Review
  11. Pannexin1 channels in the liver: an open enemy.Frontiers in cell and developmental biology · 2023
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. The protective effect of rheumatic disease agents in COVID-19.Best practice & research. Clinical rheumatology · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Sheng GuoInstitute of Immunology, PLA, Third Military Medical University, Chongqing, China.
Chengying YangInstitute of Immunology, PLA, Third Military Medical University, Chongqing, China.
Bo DiaoInstitute of Immunology, PLA, Third Military Medical University, Chongqing, China.
Xiaoyong HuangInstitute of Immunology, PLA, Third Military Medical University, Chongqing, China.
Meihua JinDepartment of Pharmacology, Yanbian University, Yanji, Jilin province, China.
Lili ChenDepartment of Basic Medicine, Yanbian University, Yanji, Jilin province, China.
Weiming YanDepartment and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Qin NingDepartment and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Lixin ZhengLaboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Yuzhang WuInstitute of Immunology, PLA, Third Military Medical University, Chongqing, China.
Yongwen ChenInstitute of Immunology, PLA, Third Military Medical University, Chongqing, China.
Army Medical University · CNYanbian University · CNHuazhong University of Science and Technology · CNNational Institutes of Health · USTongji Hospital · CN

Funding

Intramural NIH HHS
6 · The paper itself

Abstract

Viral fulminant hepatitis (FH) is a severe disease with high mortality resulting from excessive inflammation in the infected liver. Clinical interventions have been inefficient due to the lack of knowledge for inflammatory pathogenesis in the virus-infected liver. We show that wild-type mice infected with murine hepatitis virus strain-3 (MHV-3), a model for viral FH, manifest with severe disease and high mortality in association with a significant elevation in IL-1β expression in the serum and liver. Whereas, the viral infection in IL-1β receptor-I deficient (IL-1R1-/-) or IL-1R antagonist (IL-1Ra) treated mice, show reductions in virus replication, disease progress and mortality. IL-1R1 deficiency appears to debilitate the virus-induced fibrinogen-like protein-2 (FGL2) production in macrophages and CD45+Gr-1high neutrophil infiltration in the liver. The quick release of reactive oxygen species (ROS) by the infected macrophages suggests a plausible viral initiation of NLRP3 inflammasome activation. Further experiments show that mice deficient of p47phox, a nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunit that controls acute ROS production, present with reductions in NLRP3 inflammasome activation and subsequent IL-1β secretion during viral infection, which appears to be responsible for acquiring resilience to viral FH. Moreover, viral infected animals in deficiencies of NLRP3 and Caspase-1, two essential components of the inflammasome complex, also have reduced IL-1β induction along with ameliorated hepatitis. Our results demonstrate that the ROS/NLRP3/IL-1β axis institutes an essential signaling pathway, which is over activated and directly causes the severe liver disease during viral infection, which sheds light on development of efficient treatments for human viral FH and other severe inflammatory diseases.

Indexed as

Host-Pathogen InteractionsAnimalsCarrier ProteinsCoronavirus InfectionsDisease ProgressionFibrinogenImmunity, InnateInflammasomesInterleukin-1betaInterleukin 1 Receptor Antagonist ProteinLiverMacrophagesMiceMice, Inbred C57BLMice, KnockoutMurine hepatitis virusCarrier ProteinsFgl2 protein, mouseFibrinogenIL1B protein, mouseIL1R1 protein, mouseInflammasomesInterleukin-1betaInterleukin 1 Receptor Antagonist ProteinNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouseReactive Oxygen SpeciesReceptors, Interleukin-1 Type IRecombinant Proteins

Identifiers

PMID26367131
PMCPMC4569300
OpenAlexW1955132430

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.